

Merck beats Q3 estimates on oncology strength and raised guidance, while Guggenheim eyes pipeline progress ahead of Keytruda patent loss.
You can purchase shares of Merck & Co (NYSE:MRK) through any online brokerage.
Other companies in Merck & Co’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Novartis AG (NYSE:NVS), AstraZeneca PLC (NYSE:AZN) and Novo Nordisk AS (NYSE:NVO).
Merck & Co has a consensus price target of $147.45.
The stock price for Merck & Co (NYSE: MRK) is $144.38 last updated November 6, 2026 at 4:32 AM EST.
There are no upcoming dividends for Merck & Co.
Merck & Co does not have any upcoming earnings scheduled.
There is no upcoming split for Merck & Co.
Merck & Co is in the Health Care sector and Pharmaceuticals industry. They are listed on the NYSE.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to...